Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates
- PMID: 20425089
- DOI: 10.1007/s11914-010-0007-2
Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates
Abstract
Several case series and multiple individual case reports suggest that some subtrochanteric and femoral shaft fractures might occur in patients who have been treated with long-term bisphosphonates. Several unique clinical and radiographic features are emerging: prodromal thigh pain prior to the fracture, complete absence of trauma precipitating the fracture, and bilateral fractures in some patients. Radiographic features include presence of stress reaction, transverse or short oblique fractures, and thick femoral cortices. The overall incidence of subtrochanteric and shaft fractures combined is below 30 per 100,000 person-years, so this type of fracture is much less common than proximal femur (hip) fracture. Furthermore, the unique "atypical" fracture type is a subset of all subtrochanteric and femoral shaft fractures. The putative mechanism is unknown, and more research is needed to identify distinctive characteristics and the pathophysiology of these atypical fractures. There is no rationale to withhold bisphosphonate therapy from patients with osteoporosis, although continued use of bisphosphonate therapy beyond a treatment period of 3 to 5 years should be re-evaluated annually.
Similar articles
-
Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.Osteoporos Int. 2014 Aug;25(8):2109-16. doi: 10.1007/s00198-014-2738-x. Epub 2014 May 21. Osteoporos Int. 2014. PMID: 24846316 Free PMC article.
-
Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy.Bone. 2012 Sep;51(3):524-7. doi: 10.1016/j.bone.2012.05.010. Epub 2012 May 23. Bone. 2012. PMID: 22634175
-
Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24. N Engl J Med. 2010. PMID: 20335571
-
[Femur fractures caused by long-term bisphosphonate therapy].Ned Tijdschr Geneeskd. 2010;154:A1218. Ned Tijdschr Geneeskd. 2010. PMID: 20619008 Review. Dutch.
-
[Atypical femoral fracture associated with the use of bisphosphonates, an adverse drug reaction not to be missed].Rev Med Suisse. 2012 Jun 6;8(344):1238-42. Rev Med Suisse. 2012. PMID: 22730621 Review. French.
Cited by
-
Peptidomimetic inhibitor of L-plastin reduces osteoclastic bone resorption in aging female mice.Bone Res. 2021 Apr 9;9(1):22. doi: 10.1038/s41413-020-00135-9. Bone Res. 2021. PMID: 33837180 Free PMC article.
-
Bone regeneration with umbilical cord blood mesenchymal stem cells in femoral defects of ovariectomized rats.Osteoporos Sarcopenia. 2018 Sep;4(3):95-101. doi: 10.1016/j.afos.2018.08.003. Epub 2018 Sep 26. Osteoporos Sarcopenia. 2018. PMID: 30775550 Free PMC article.
-
Review: epidemiology and pathophysiology of atypical femur fractures.Curr Osteoporos Rep. 2014 Mar;12(1):65-73. doi: 10.1007/s11914-014-0198-z. Curr Osteoporos Rep. 2014. PMID: 24526234 Review.
-
Atypical Complete Femoral Fractures Associated with Bisphosphonate Use or Not Associated with Bisphosphonate Use: Is There a Difference?Biomed Res Int. 2016;2016:4753170. doi: 10.1155/2016/4753170. Epub 2016 Nov 20. Biomed Res Int. 2016. PMID: 27990429 Free PMC article.
-
Asperosaponin VI promotes bone marrow stromal cell osteogenic differentiation through the PI3K/AKT signaling pathway in an osteoporosis model.Sci Rep. 2016 Oct 19;6:35233. doi: 10.1038/srep35233. Sci Rep. 2016. PMID: 27756897 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical